Skip to main content
Natera, Inc. logo

Natera, Inc. — Investor Relations & Filings

Ticker · NTRA ISIN · US6323071042 LEI · 529900CQ3OZ0A0VYVU59 US Human health and social work activities
Open in API
Filings indexed 1,585 across all filing types
Latest filing 2019-01-08 Board/Management Inform…
Country US United States of America
Listing US NTRA

About Natera, Inc.

https://www.natera.com/

Natera, Inc. is a diagnostics company specializing in cell-free DNA (cfDNA) testing. The company develops and commercializes non-invasive tests focused on three primary areas: women's health, oncology, and organ health. In women's health, its products include the Panorama non-invasive prenatal test (NIPT) and the Horizon carrier screening test to assess genetic risks. The oncology portfolio features Signatera, a personalized molecular residual disease (MRD) test used to monitor cancer recurrence and treatment response. For organ health, its tests are designed to detect early signs of transplant rejection. Natera's technology aims to provide actionable information for personalized medical care, supported by extensive clinical validation through numerous peer-reviewed studies.

Recent filings

Filing Released Lang Actions
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the departure and appointment of key executives, including the resignation of the CEO, appointment of a new CEO and COO, changes in board membership, and related employment agreements and compensatory arrangements. There are no financial statements or detailed financial performance data presented. The primary subject is changes in the company's board of directors and senior management. Therefore, this document fits the category of Board/Management Information (MANG). The document length is sufficient and the content is detailed about management changes, not just an announcement or summary, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2019-01-08 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a credit agreement, specifically a financing arrangement involving a senior secured term loan facility. It details the increase in the delayed draw amount and extension of the deadline, as well as changes to the interest rate. There is no detailed financial statement or comprehensive financial analysis, but rather an update on financing terms and obligations. The document length is 4166 characters, which is relatively short and focused on a financing update. According to the filing definitions, updates on company fundraising, financing activities, or capital structure changes fall under Capital/Financing Update (CAP). Therefore, this document is best classified as a Capital/Financing Update (CAP).
2019-01-07 English
4 Filing
Director's Dealing
2018-12-26 English
4 Filing
Director's Dealing
2018-12-26 English
4 Filing
Director's Dealing
2018-12-26 English
10-Q Filing
Interim / Quarterly Report Q3 2018
2018-11-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.